Innoviva Market Cap 2010-2025 | INVA

Innoviva market cap history and chart from 2010 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Innoviva market cap as of July 11, 2025 is $1.2B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.196B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $749.327B 57.46
Johnson & Johnson (JNJ) United States $379.414B 15.69
AbbVie (ABBV) United States $344.449B 18.99
Novo Nordisk (NVO) Denmark $317.060B 21.01
Roche Holding AG (RHHBY) Switzerland $262.899B 0.00
Novartis AG (NVS) Switzerland $261.370B 14.93
Merck (MRK) United States $210.977B 10.79
Pfizer (PFE) United States $146.569B 8.03
Sanofi (SNY) France $121.004B 11.92
Bayer (BAYRY) Germany $31.909B 6.50